Glycosmedia needs your testimonials
As part of our fundraising efforts we are inviting the submission of testimonials that will be added to the “Comments” section on Glycosmedia. Please send your testimonials along with your name, occupation / position and organisation to the editor Jim Young on jim@glycosmedia.com Thank you
A laboratory standpoint on the role of hemoglobin A1c for the diagnosis of diabetes in childhood: more doubts than certainties?
Taken together, the current limitations would suggest a certain degree of caution before recommending the widespread implementation of the A1c assay for diagnosing diabetes in childhood and adolescence (Pediatric Diabetes)
Improved A1C by switching to continuous subcutaneous insulin infusion from injection insulin therapy in type 2 diabetes: A retrospective claims analysis
CSII was associated with significant reductions in A1C without an increase in hypoglycemic events in insulin-taking people with type 2 diabetes, including subjects previously using a long-acting and rapid-acting insulin regimen (Primary Care Diabetes)
New evidence for a role of melatonin in glucose regulation
This review discusses the impact of melatonin on insulin secretion transmitted through both the pertussis-toxin-sensitive membrane receptors MT1 (MTNR1a) and MT2 (MTNR1b) and the second messengers cAMP, cGMP and IP3 (Clinical Endocrinology & Metabolism)
Association between alcohol consumption and diabetic retinopathy and visual acuity—the AdRem Study
Alcohol consumption is associated with increased risk of deterioration of visual acuity, but not with retinopathy in individuals with Type 2 diabetes (Diabetic Medicine)
Diabetic retinopathy screening using tele-ophthalmology in a primary care setting
We concluded that adequately trained GPs can screen for treatable lesions of diabetic retinopathy with a very high level of reliability using non-mydriatic retinography (Journal of Telemedicine)
Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial
Four years after treatment with GAD-alum, children and adolescents with recent-onset type 1 diabetes continue to show no adverse events and possibly to show clinically relevant preservation of C-peptide (Diabetologia)
Buccal spray insulin in subjects with impaired glucose tolerance: the prevoral study
This proof-of-concept study demonstrates that treatment with buccal spray insulin is a simple and valuable therapy for reducing postprandial hyperglycaemia in obese subjects with IGT (Ingenta Connect)
Diabetes, cardiovascular drug developer PhaseBio adds $15M
The Philadelphia-area biopharma company PhaseBio Pharmaceuticals has received the final $15 million of a $25 million investment to fund further testing of its lead drug, which focuses on hyperglycemia related to Type 2 diabetes (Medcity News)
Current medical management of diabetic foot infections
This article examines the potential role of standard and newer antibiotics that may be appropriate for treating diabetic foot infections, including ertapenem, vancomycin, moxifloxacin, daptomycin, telavancin and tigecycline, as well as several investigational agents, such as dalbavancin, ceftobiprole and nemonoxacin (Expert Reviews)
Final date to change to Mixtard 30 alternative
Anyone who is still using the insulin Mixtard 30 is being urged to consult their GP as a matter of urgency to ensure they are changed onto an alternative treatment before the medication is withdrawn on 31 December 2010 (Diabetes UK)
Glycosmedia is also available as an App: